加拿大乳腺癌实践指南:关于HR+/HER2-早期乳腺癌患者2025年系统治疗的全国共识建议

Sandeep Sehdev1, Anil Abraham Joy2, Jean-François Boileau3

  • 1The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.

PubMed
概括

加拿大对激素受体阳性,HER2阴性早期乳腺癌 (HR+/HER2-EBC) 的指导方针强调量身定制的治疗. 关键建议包括选择性化疗,基因组测试,内分泌疗法,高风险患者的CDK4/6抑制剂,以及减少复发的双酸盐.

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K